



UNITED STATE EPARTMENT OF COMMERCE United States Patent and Trademark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	AT	ATTORNEY DOCKET NO.	
			FX	AMINER	
		İ			
			ART UNIT	PAPER NUMBER	
			DATE MAIL ED.		

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trademarks

Office Action Summary

Application No. 09/665,036

Applicant(s)

Examiner

Patricia Patten

Art Unit

1651

llic et al.

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136 (a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). - Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b). Status Responsive to communication(s) filed on 1) 2a) This action is FINAL. 2b) X. This action is non-final. 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11; 453 O.G. 213. Disposition of Claims is/are pending in the application. 4) X Claim(s) 1-18 4a) Of the above, claim(s) is/are withdrawn from consideration. is/are allowed. 5) Claim(s) Claim(s) ______ is/are rejected. is/are objected to. Claim(s) are subject to restriction and/or election requirement. 8) X. Claims 1-18 Application Papers 9) The specification is objected to by the Examiner. The drawing(s) filed on is/are objected to by the Examiner. 10) The proposed drawing correction filed on is: a) approved b) disapproved. 11) The oath or declaration is objected to by the Examiner. 12). Priority under 35 U.S.C. § 119 Acknowledgement is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d). Some* c) None of: 1. ... Certified copies of the priority documents have been received. Certified copies of the priority documents have been received in Application No. 2. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). *See the attached detailed Office action for a list of the certified copies not received. Acknowledgement is made of a claim for domestic priority under 35 U.S.C. § 119(e). 14) Attachment(s) Notice of References Cited (PTO-892) 181 Interview Summary (PTO 413) Paper No(s) Notice of Draftsperson's Patent Drawing Review (PTO-948) Notice of Informal Patent Application (PTO-152) 161

Information Disclosure Statement(s) (PTO-1449) Paper No(s).

201

Application/Control Number: 09/665,036

Art Unit: 1651

DETAILED ACTION

Election/Restriction

Restriction to one of the following inventions is required under 35 U.S.C. 121:

- Claims 1-4, 11-14 and 16-17, drawn to a composition comprising substances
 obtained from cuticular or epicuticular layers of a plant or plant part, classified in
 class 424, subclass 724 for example.
- II. Claims 5-10, drawn to a method for producing a preparation possessing antiviral activity from the cuticular or epicuticular layers of a plant or plant part, and a product derived therefrom, classified in class 424, subclass 723 for example.
- III. Claims 15 and 18, drawn to a method for treating a viral disease in a patient comprising administration of the composition of Claim 11, classified in class 424, subclass 725 for example.

The inventions are distinct, each from the other because of the following reasons:

Inventions I and II are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case the different

Art Unit: 1651

Groups recite respective products which may be produced by different means. Group I is not drawn to any specific product, and thus, the product of Group I may be obtained by a materially different method than the one recited in Group II. The product obtained from the process of Group II could therefore be materially different than the product of Group I, causing the product to possess different functions and/or effects when administered to an individual.

Inventions I and III are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case there are numerous plant, bacterial as well as animal extracts which are known in the art for treating viral diseases.

The search for each of the above inventions is not co-extensive particularly with regard to the non-patent literature search. Further, a reference which would anticipate the invention of one group would not necessarily anticipate or even make obvious another group.

Because these inventions are distinct for the reasons given above and the search required for each Group is not required for the others, restriction for examination purposes as indicated is proper.

This application contains claims directed to the following patentably distinct species of the claimed invention: All of the distinct genus set forth in Claim 2 as well as all of the distinct constituents listed in Claim 3.

Application/Control Number: 09/665,036

Art Unit: 1651

Applicant is required under 35 U.S.C. 121 to elect a single disclosed species from Claim 2 as well as a single constituent from Claim 3 for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable. Currently, Claims 2 and 3 are generic.

Applicant is advised that a reply to this requirement must include an identification of the species that is elected consonant with this requirement, and a listing of all claims readable thereon, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered nonresponsive unless accompanied by an election.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP § 809.02(a).

Should applicant traverse on the ground that the species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.

A telephone call was made to William K. Merkel on 4/19/01 to request an oral election to the above restriction requirement, but did not result in an election being made.

Application/Control Number: 09/665,036

Page 5

Art Unit: 1651

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a petition under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(1).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to examiner Patricia Patten, whose telephone number is (703)308-1189. The examiner can normally be reached on M-F from 9am to 5pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Michael Wityshyn, can be reached on (703) 308-4743. The fax phone number for the organization where this application or proceeding is assigned is (703) 308-4242.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-0196.

FRANCISCO PRATS
PRIMARY EXAMINER